Seguir
Bruno L. Abbadi
Bruno L. Abbadi
Postdoctoral Researcher at Rutgers University
E-mail confirmado em rutgers.edu
Título
Citado por
Citado por
Ano
2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
K Pissinate, AD Villela, V Rodrigues-Junior, BC Giacobbo, ES Grams, ...
ACS medicinal chemistry letters 7 (3), 235-239, 2016
542016
New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy) acetamides against Mycobacterium tuberculosis
BC Giacobbo, K Pissinate, V Rodrigues-Junior, AD Villela, ES Grams, ...
European Journal of Medicinal Chemistry 126, 491-501, 2017
482017
Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis
KH Antunes, RT Stein, C Franceschina, EF da Silva, DN de Freitas, ...
EBioMedicine 77, 2022
432022
Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy) acetamide-based antituberculosis agents
AF Borsoi, JD Paz, BL Abbadi, FS Macchi, N Sperotto, K Pissinate, ...
European Journal of Medicinal Chemistry 192, 112179, 2020
362020
1H-Benzo [d] imidazoles and 3, 4-dihydroquinazolin-4-ones: Design, synthesis and antitubercular activity
FS Macchi, K Pissinate, AD Villela, BL Abbadi, V Rodrigues-Junior, ...
European Journal of Medicinal Chemistry 155, 153-164, 2018
272018
Activity of 2-(quinolin-4-yloxy) acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing
FT Subtil, AD Villela, BL Abbadi, VS Rodrigues-Junior, CV Bizarro, ...
International Journal of Antimicrobial Agents 51 (3), 378-384, 2018
272018
Synthesis and mechanistic investigation of iron (II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy
J Laborde, C Deraeve, FG de Mesquita Vieira, A Sournia-Saquet, ...
Journal of Inorganic Biochemistry 179, 71-81, 2018
242018
Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection
VS Rodrigues-Junior, AD Villela, RSB Gonçalves, BL Abbadi, ...
International journal of antimicrobial agents 48 (2), 203-207, 2016
242016
Handling the hurdles on the way to anti-tuberculosis drug development
PF Dalberto, EV De Souza, BL Abbadi, CE Neves, RS Rambo, AS Ramos, ...
Frontiers in Chemistry 8, 586294, 2020
222020
Anti-tubercular profile of new selenium-menadione conjugates against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain and multidrug-resistant clinical isolates
RCB Ribeiro, DB de Marins, I Di Leo, L da Silva Gomes, MG de Moraes, ...
European Journal of Medicinal Chemistry 209, 112859, 2021
182021
Synthesis and photophysical, thermal and antimycobacterial properties of novel 6-amino-2-alkyl (aryl/heteroaryl)-4-(trifluoromethyl) quinolines
YG Kappenberg, A Ketzer, FS Stefanello, PRS Salbego, TV Acunha, ...
New Journal of Chemistry 43 (31), 12375-12384, 2019
172019
Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis
TC Muradás, BL Abbadi, AD Villela, FS Macchi, PF Bergo, TF de Freitas, ...
PLoS One 13 (8), e0202568, 2018
172018
Is IQG-607 a potential metallodrug or metallopro-drug with a defined molecular target in Mycobacterium tuberculosis?
BL Abbadi, VS Rodrigues-Junior, AS Dadda, K Pissinate, AD Villela, ...
Frontiers in Microbiology 9, 364546, 2018
162018
Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme
LKB Martinelli, M Rotta, AD Villela, VS Rodrigues-Junior, BL Abbadi, ...
Scientific Reports 7 (1), 46696, 2017
162017
Revisiting activation of and mechanism of resistance to compound IQG-607 in Mycobacterium tuberculosis
BL Abbadi, AD Villela, VS Rodrigues-Junior, FT Subtil, PF Dalberto, ...
Antimicrobial Agents and Chemotherapy 62 (2), 10.1128/aac. 02222-17, 2018
142018
Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation
JD Paz, ND de Moura Sperotto, AS Ramos, K Pissinate, VSR Junior, ...
European Journal of Medicinal Chemistry 245, 114908, 2023
112023
Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy
VS Rodrigues-Junior, AD Villela, BL Abbadi, NDM Sperotto, K Pissinate, ...
Regulatory Toxicology and Pharmacology 111, 104553, 2020
102020
Antitubercular activity of novel 2-(quinoline-4-yloxy) acetamides with improved drug-like properties
AF Borsoi, LM Alice, N Sperotto, AS Ramos, BL Abbadi, FS Macchi Hopf, ...
ACS Medicinal Chemistry Letters 13 (8), 1337-1344, 2022
92022
Pentacyanoferrate (II) complex of pyridine-4-and pyrazine-2-hydroxamic acid as source of HNO: investigation of anti-tubercular and vasodilation activities
EM Carvalho, T de Freitas Paulo, AS Saquet, BL Abbadi, FS Macchi, ...
JBIC Journal of Biological Inorganic Chemistry 25, 887-901, 2020
92020
Assessing the role of deoD gene in Mycobacterium tuberculosis in vitro growth and macrophage infection
PF Dalberto, V Rodrigues-Junior, VCA Falcão, AFM Pinto, BL Abbadi, ...
Microbial Pathogenesis 119, 60-64, 2018
52018
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20